新闻通稿

/新闻通稿

Oramed to Present at 3rd Annual Clinical Trials Summit

NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April [...]

2019-04-11T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Patent Allowed in the U.S. for Oral Exenatide

NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been [...]

2019-04-04T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at H.C. Wainwright Global Life Sciences Conference

NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright Global Life Sciences Conference, taking place [...]

2019-04-03T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for [...]

2019-03-28T08:40:00+00:00 Categories: 新闻通稿|Tags: |

Chinese Regulatory Authority [NMPA] Approves IND Application of Oramed’s Oral Insulin Capsules

NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of [...]

2019-03-26T08:40:00+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place [...]

2019-02-06T08:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Initiates Phase I Oral GLP-1 Study Under IND

JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 [...]

2019-01-22T08:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals’ CEO Letter to Shareholders

JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our partners HTIT, thereby increasing our total payments from HTIT received [...]

2019-01-15T08:55:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Receives Additional $3 Million Milestone Payment from HTIT

Totaling $33 M in payments from HTIT received to date JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of [...]

2019-01-09T08:40:00+00:00 Categories: 新闻通稿|Tags: |